Pharmaceutical Technology

JANUARY 6, 2023

In the case of Novartis’ antihypertensive drug Exforge (amlodipine and valsartan), retail pharmacies including CVS, Walgreens, and two other plaintiff groups accused Novartis and Endo International’s Par Pharmaceutical unit of forming an illegal “reverse payment” agreement to delay the launch of less expensive generic versions of the drug.

Pharmaceutical 97

Pharmaceutical Doctors Healthcare Provider Prescription 97

pharmaphorum

DECEMBER 29, 2022

The FDA granted full approval to Par’s generic on 28 March, 2013. Plaintiffs – in this case direct purchasers, indirect purchasers and retailers including CVS Health, Kroger, Rite Aid and Walgreens Boots Alliance according to Reuters – filed suit against Novartis and Par in 2018 alleging violation of federal antitrust laws.

Retail 52

Retail Marketing Doctors Government 52

Cadensee

JULY 14, 2021

They've been involved in major clinical studies; they've been working with the FDA as consultants. Then if it that's going to be the case, you're going to sit there for the FDA approval. So not only M&As, the tech, the retail, the pharma that are buying. Because guess what? It's not always going to happen.

Marketing 52

Marketing Doctors Medical Management 52

pharmaphorum

JANUARY 12, 2023

The Attorney General of Alabama has threatened to use an obscure law passed in 2006 to prosecute women who terminate a pregnancy using pharmacological means, shortly after the FDA made access to the drugs easier.

Pharmacology 52

Pharmacology Retail Healthcare Provider FDA 52